[ad_1]
NEW HAVEN, Conn., March 1, 2024 (Globe Newswire) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company that leverages artificial intelligence to develop innovative medicines in neuroscience and immuno-oncology. ) announced today that the company’s fourth-quarter and full-year 2023 financial results will be announced on Tuesday, March 12, 2024, before the opening of U.S. financial markets. BioXcel Therapeutics’ management will also host a conference call and his own webcast on the same day at 8 a.m. Eastern Time to discuss the company’s financial results and provide a general business update.
|
Conference call and webcast details |
|
|
Date Time: |
Tuesday, March 12, 2024, 8:00 a.m. ET |
|
Domestic: |
877-407-5795 |
|
International: |
201-689-8722 |
The webcast link can be accessed under “News/Events” on the “Investors and Media” page of our website. www.bioxceltherapeutics.com.
|
Replay* |
|
|
Domestic: |
877-660-6853 |
|
International: |
201-612-7415 |
|
Conference ID: |
13744874 |
*Replay available until June 12, 2024
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company that uses artificial intelligence to develop innovative medicines in neuroscience. His wholly owned subsidiary, OnkosXcel Therapeutics, focuses on drug development in immuno-oncology. The company’s drug re-innovation approach leverages existing approved drugs and clinically validated product candidates, along with big data and proprietary machine learning algorithms, to identify new therapeutic indications. Learn more about. bioxceltherapeutics.com.
Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements will be subject to the forward-looking statement safe harbor provisions contained in Section 27A of the Securities. Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release, other than statements of historical fact, including, without limitation, the date and time of the release of the Company’s fourth quarter and full year 2023 financial results and related conference calls, are forward-looking statements. These statements should be considered forward-looking statements. As used herein, “anticipate,” “believe,” “could,” “continue,” “could,” “designed,” “estimate,” “anticipate,” Words like “anticipate,” “goal,” and “intend” are used. “may”, “might”, “plan”, “could”, “could”, “anticipate”, “anticipate”, “should”, “target and “will,” “will,” “will” and similar expressions are for identification purposes. However, not all forward-looking statements contain these words or expressions. Additionally, statements and information, including underlying assumptions, that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or conditions are forward-looking. All forward-looking statements are based on the Company’s current expectations and various assumptions. Although the Company believes that its expectations and beliefs have a reasonable basis, they are inherently uncertain. We may not realize our expectations and our beliefs may not prove to be correct. Actual results may differ materially from those described or implied by such forward-looking statements as a result of various important factors. These include, but are not limited to, the important factors described under the caption “Risk Factors” in our Quarterly Report on Form 10-Q. as such factors may be updated from time to time in our other filings with the SEC, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended December 31, 2023; , accessible from the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated in the forward-looking statements contained in this press release. Such forward-looking statements represent management’s expectations as of the date of this press release. We may choose to update such forward-looking statements at some point in the future, unless required by law, even if subsequent events cause our views to change. , has no obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
contact address
For companies
Bio Excel Therapeutics
Eric Kopp
1.203.494.7062
ekopp@bioxceltherapeutics.com
PR for investors
Bio Excel Therapeutics
brennan doyle
1.475.355.8462
bdoyle@bioxceltherapeutics.com
media
Russo Partners
david shul
1.858-717-2310
David.schull@russopartnersllc.com
Scott Stakowiak
1.646-942-5630
Scott.stachowiak@russopartnersllc.com
Source: BioXcel Therapeutics, Inc.
BT BIOXCEL THERAPEUTICS is a registered trademark of BioXcel Therapeutics, Inc.
All other trademarks are the property of their respective owners.
Copyright © 2024, BioXcel Therapeutics, Inc. All rights reserved.
[ad_2]
Source link
